Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Profit growth for Orkla’s portfolio companies

Orkla’s operating revenues increased by 14% in the third quarter to NOK 16.8 billion. The improvement is primarily due to price increases and positive currency translation effects. Eight out of 12 portfolio companies had underlying profit growth.Orkla’s consolidated portfolio companies increased operating profit EBIT (adj.) by 16% to NOK 1.8 billion in the third quarter. The profit contribution from associates amounted to NOK 509 million, an improvement of 114%. Jotun (42.7% interest) was the main contributor to this improvement. Jotun’s profit was driven by volume growth, higher gross

Interim report January–September 2023

Eastnine has a very stable financial position following the sale of the holding in Melon Fashion Group (MFG) in August and the redemption of Eastnine’s sole bond at the beginning of October. Profit from property management for the quarter and the period reached new record highs. Interest income, a larger property portfolio, and a higher average occupancy rate and rent levels impacted positively.January–September 2023 · Rental income increased by 25 per cent to EUR 27,200k (21,804), as a result of a larger property portfolio as well as a higher average occupancy rate and rent level

CapMan Plc 1–9 2023 Interim Report

CapMan PlcStock Exchange Release / Interim Financial Report26 October 2023 at 8:00 a.m. EEST CapMan Plc 1–9 2023 Interim Report Results and significant events in 1–9 2023: · Group turnover was MEUR 45.3 1 January–30 September 2023 (MEUR 47.8 1 January–30 September 2022) and decreased by 5 per cent. · Group turnover excluding carried interest, i.e., fee income was MEUR 42.3 (42.3).  · Operating profit was MEUR 9.5 (MEUR 45.6). · Fee profit, i.e., operating profit excluding carried interest and fair value changes, was MEUR 8.3 (MEUR 7.7) and increased by 7 per cent.

Solteq Plc’s Interim Report January 1 – September 30, 2023

Stock Exchange Bulletin Interim ReportOctober 26, 2023, at 8.00 am EETSolteq returned to a growth path, heavy cost structure burdened the Utilities segment July–September · Comparable revenue totaled EUR 12.2 million (12.0) and increased by 1.9 percent. Revenue totaled EUR 12.2 million (14.4) and decreased by 14.9 percent · Comparable EBITDA was EUR 0.6 million (0.6) and EBITDA EUR 0.5 million (0.8). Comparable EBITDA percent was 4.6 (4.7) · Comparable operating result was EUR -0.7 million (-0.7) and operating result EUR -0.7 million (-5.0). Comparable operating result

Swedbank’s Interim report for the third quarter 2023

Swedbank´s President and CEO Jens Henriksson comments: ”Another strong result in a weaker economy”.· Slightly higher income in the quarter – stable volumes  · Lower expenses – cost/income ratio 0.30  · Solid credit quality despite weaker macroeconomic outlook and ratings migration · Strong capitalisation and strong liquidity  · Swedbank issued first ever social bond by a Nordic bank  · Swedbank establishes the Institute for Financial Health to promote financial literacy Contact:Annie Ho (annie.ho@swedbank.com), Head of Investor Relations, +46 70 343 7815

Tietoevry's Interim Report 3/2023: Mixed performance in a softer market

Tietoevry Corporation INTERIM REPORT  26 October 2023, 8.00 a.m. EEST    •         Growth 2% – solid performance in software businesses, weaker demand in Tietoevry Create and Tech Services  •         Profitability of 13% despite softer market and continued high inflation – improved profitability in Tietoevry Industry and Tech Services •         MentorMate acquisition closed in the third quarter – business performance and integration progressing as planned •         Strategic reviews of Tietoevry Banking and Tech Services on track with earlier announced schedules   The

Hansa Biopharma Interim Report January-September 2023

•    Encouraging high-level results for first-in-human trial of HNSA-5487•    Well attended Hansa-sponsored symposium at ESOT focusing on first patient experiences•    Dr. Hitto Kaufmann appointed new CSOLund, Sweden, October 26, 2023, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January to September 2023. Highlights for the third quarter of 2023 · Total Q3 revenue of SEK 22.8m including SEK 16.5m in product sales and SEK 5.7m under our agreement with Sarepta ·

Sedana Medical AB’s Interim report January-September 2023

All-time-high Q3 sales and further steps towards ex-US profitabilityThird quarter 2023 · Net sales for the quarter totalled MSEK 34.3 (26.5), equivalent to an increase of 29% compared to the same quarter 2022. At constant exchange rates, sales increased by 16%. · Gross profit was MSEK 23.9 (18.4) equivalent to a margin of 70% (70%). · Earnings before interest, taxes, depreciation and amortisation (EBITDA) totalled MSEK -12.6 (-25.1), equivalent to an EBITDA margin of -37% (-95%). EBITDA ex-US for the quarter was MSEK -11.5 (-22.8). · Operating income (EBIT) totalled MSEK -18.1

Kesko interim report 1 Jan. -30 Sept. 2023: A fine performance in a weak market

FINANCIAL PERFORMANCE IN BRIEF: 7-9/2023 · Group net sales in July-September totalled €2,949.1 million (€3,009.8 million). Reported net sales were down by 2.0%, in comparable terms net sales decreased by 2.7% · Comparable operating profit totalled €208.1 million (€242.8 million) · Operating profit totalled €206.6 million (€242.4 million) · Cash flow from operating activities totalled €394.9 million (€318.8 million) · Comparable earnings per share €0.38 (€0.47), reported earnings per share €0.37 (€0.47) 1-9/2023 · Group net sales in January-September totalled €8,

Volvo Cars Q3 results: momentum continues while performing and transforming

· Q3 revenue was SEK 92 bn (SEK 79 bn in Q3 2022) · Q3 operating income (excluding JVs and associates) was SEK 6.1 bn (SEK 3.5 bn in Q3 2022) · Q3 operating income was SEK 4.5 bn (SEK 2.1 bn in Q3 2022) · Q3 EBIT margin (excluding JVs and associates) was 6.7 per cent (4.4 per cent in Q3 2022) · Q3 EBIT margin was 4.8 per cent (2.6 per cent in Q3 2022) · Q3 basic earnings per share was SEK 1.01 (SEK 0.11 in Q3 2022) · Q3 fully electric car sales share at 13 per cent (7 per cent in Q3 2022)   Volvo Cars today reports an almost 75 per cent increase in operating profits,

ICA Gruppen’s report for the third quarter 2023

Price investments start to have an effect – improved volume growth and stable earnings· Sales in ICA Sweden’s grocery retail business increased by 4.1% compared with the same quarter in 2022 at the same time as earnings development was stagnant and the margin fell from 4.7% to 4.5%. · Sales for ICA Gruppen as a whole rose in Q3, mainly driven by high inflation, to SEK 36,943 million (SEK 34,544 million in 2022). The operating margin landed at 5.3% (4.9%) and operating profit at SEK 1,815 million (1,629). · Rimi Baltic delivered stable earnings but competition is razor-sharp with a

Montinutra raises €2M to turn forest industry sidestreams into bio-alternatives, replacing fossil-based ingredients in the chemical and cosmetics industries

Metsä Spring’s portfolio company’s unique, zero-waste, and commercial-ready innovation turns forest industry sidestreams such as sawdust into natural, non-GMO, and biodegradable biochemicals, significantly cutting CO2 emissions compared to fossil-based alternatives.ESPOO, Finland (October 26th, 2023) – Montinutra  has raised €2M in pre-A funding led by Metsä Spring , a corporate venture unit of Metsä Group , with a syndicate of private investors.   Founded in 2018, Montinutra transforms forest industry

Orkla announces OFI partnership with Rhône

Orkla today announced a partnership with Rhône, a global private equity firm with a focus on investments in businesses with a transatlantic presence. Investment funds affiliated with Rhône will acquire 40% ownership in Orkla Food Ingredients AS (“OFI”). The transaction implies an enterprise value of NOK 15.5 billion.Orkla and Rhône expect that the partnership will enable the OFI group to continue on its growth journey. The Rhône team has experience in the consumer sector and food and beverage industry through past and current investments. The partnership with Rhône aims to build upon and

One more leading global airline selects Loyal Solutions technology

Cathay Pacific and Loyal Solutions have entered a multi-year contract where Loyal Solutions will provide its market leading card-linking SaaS platform, LoyalTfacts[®] to power further innovation for Cathay`s successful Asia Miles program.LoyalTfacts[® ]will enable Cathay members to earn or redeem Asia Miles across a wide range of partners simply by paying with a linked Visa or Mastercard. Peter Kisbye, Founder and CEO of Loyal Solutions:” Everyone at Loyal Solutions are very proud that Cathay Pacific after a rigorous process have selected our market leading loyalty technology platform,

OKEA ASA - Third quarter 2023 financial results

(Trondheim, 26 October 2023) - OKEA ASA (OSE: OKEA) delivered operating income of NOK 2,105 (1,707) million and EBITDA of NOK 1,336 (1,167) million in the third quarter of 2023. Net profit after tax amounted to NOK 32 (69) million.(Amounts in parentheses refer to previous quarter) “Production performance in the quarter was good, particularly on our operated assets. In combination with increased liquids prices, this resulted in solid total operating income and EBITDA. However, the reduction in reserve estimates for the Yme field caused an impairment of NOK 475 million which reduced net

Key information relating to the cash dividend to be paid for OKEA ASA

(Trondheim, 26 October 2023) - OKEA ASA (OSE: OKEA)Dividend amount: NOK 1.00 per share Announced currency: NOK Last day including right: 30 November 2023 Ex-date: 1 December 2023 Record date: 4 December 2023 Payment date: 15 December 2023 (on or about) Date of approval: 25 October 2023 For further information, please contact: VP IR & Communication, Anca Jalba, + 47 410 87 988. This information is subject to the disclosure requirements pursuant to Oslo Rule Book II section 4.2.4.

OKEA ASA – NOK 1.00 dividend payment payable on or about 15 December

(Trondheim, 26 October 2023) - OKEA ASA (OSE: OKEA): On 11 May 2023 the annual general meeting of OKEA granted the board of directors an authorisation to approve distribution of dividends based on the company's annual accounts for 2022. The board of directors has now approved a cash dividend of NOK 1.00 per share which will be paid in December.Dividend payment in Q4 2023 The board has resolved to distribute a cash dividend payment of NOK 103.9 million (NOK 1.00 per share) in December 2023. Ex-dividend date is 1 December 2023, and record date is 4 December 2023. Payment is expected on or

DNB Markets: VEF - Mixed signals

VEF marked down its portfolio by 13% QOQ in Q3, putting YTD NAV growth at 11% (in USD), still lagging behind its portfolio peers (up 20–80% in USD). Its share price is down 19% YTD, implying a 56% discount to a fairly conservative NAV. We believe too much focus is placed on balance sheet concerns; our impression is that investors are focused on the bond maturing in Q2 2025, which could drive VEF to strengthen its balance sheet in the next 12–24 months. We note VEF’s high-beta characteristics and expect a continued recovery in long-duration growth valuation multiples, should interest rates

Getinge presents lifesaving medtech innovations at APELSO 2023

Getinge announces its commitment to APELSO 2023, set to take place in Seoul from November 2-4. Attendees will get an exclusive look at innovations from the medtech company’s acute care therapies portfolio, spotlighting advanced solutions for Extracorporeal Membrane Oxygenation (ECMO) and cardiovascular procedures. In the quest to save lives and mitigate long-term complications, the integration of innovative, sustainable solutions and cutting-edge technologies is vital. Getinge is at the forefront of offering world-class products for life support and therapies, addressing acute

Filo Discovers New High-Grade Zone at Bonita; Reports 212m at 1.15% CuEq Within 1,368m at 0.56% CuEq

VANCOUVER, BC, October 25, 2023 /CNW/ - Filo Corp. (TSX: FIL) (Nasdaq First North Growth Market: FIL) (OTCQX: FLMMF) (“Filo”, or the “Company”) is pleased to announce assay results from holes FSDH088, FSDH090 and FSDH091 from the Filo del Sol Project in San Juan, Argentina. Highlights and detailed results are shown below along with accompanying figures: · Drillhole FSDH091 intersected 1,368.0m at 0.56% CuEq from 168.0m, including: · 837.2m at 0.70% CuEq from 672.8m · 212.0m at 1.15% CuEq from 872.0m · Collared between holes FSDH060 and FSDH087, this hole continues to

How to Style Your Fireplace For Autumn

There is nothing quite like snuggling up in front of the fireplace on a cold autumn night, and it's even better when you style your fireplace for the season. An autumn fireplace can make your living room feel so much cosier and homely. Imagine having a family gathering where you're all surrounding a beautifully decorated fireplace.   [A fireplace with logs stacked in it Description automatically generated]   There are so many things you can do with your fireplace to make it look more autumn-themed. From choosing the right colour palette to adding some autumn-themed accents, it'

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

Stockholm, October 25, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data on the investigational subcutaneous formulation of LEQEMBI showing that it clears 14% more amyloid plaques as measured by PET compared to intravenous infusion (IV), with pharmacokinetics (AUC) 11% higher and similar ARIA rates. An additional analysis of the phase 3 Clarity AD data for LEQEMBI in the PET low tau population revealed that 76% of patients in the low tau population showed no decline and 60% showed clinical improvement at 18 months of treatment.The data was

Careiums AB’s Nomination Committee for the 2024 Annual General Meeting

In accordance with the decision by Careium AB’s Annual General Meeting (AGM) on April 27, 2023, the chairman of the board, Maria Khorsand, has summoned the Nomination Committee.After consultation with the major shareholders of the company as per 30 September 2023, the committee consists of the following member: • Mark Shay, Accendo Capital, appointed committee Chairman,• Richard Torgerson, Nordea Funds,• Peter Lindell, Cidro Förvaltning,• Maria Khorsand, Chairman of the Board, adjunct member of the Nomination Committee. The Nomination Committee will prepare proposals for the AGM

There are no items matching the current filter
There are no more items matching the current filter
Back to top